# Human Initialization
Timestamp: 2026-03-03T03:00:00Z

## Contributor (Immutable)

**GitHub User:** @SocialCatalystLab

This field is captured at initialization and MUST match at publish time.

## System Information

- **Claude Model:** claude-opus-4-6

## Questions Asked

1. **Country:** Which country?
   - Options: USA, France, India, Switzerland, Nigeria, United Kingdom, Other

1b. **Data focus:** Medicaid (T-MSIS) or Open topic
   - Options: Medicaid (T-MSIS), Open topic (any US policy/data)

2. **Method:** Which identification method?
   - Options: DiD (recommended), RDD, DR (Doubly Robust), Surprise me

3. **API keys:** Did you configure data API keys?
   - Options: Yes, No

4. **External review:** Include external model reviews?
   - Options: Yes (recommended), No

5. **Other preferences:** Any other preferences or constraints?

## User Responses

1. USA
1b. Open topic — Medicare Part D + CDC WONDER opioid prescribing data (not T-MSIS)
2. "you have to go into deep discovery mode here - how far can you push the structural angle, without the paper falling apart. the sweet spot. Becker-Murphy additional parameters sounds amazing. But i have no clue what is needed." — Interpreted as: sufficient statistics approach with theoretical model, reduced-form DiD estimation, and calibrated welfare counterfactuals. NOT full structural estimation.
3. Yes — all API keys configured (Census, FRED, BEA, IPUMS, etc.)
4. Yes — full external reviews + extra GPT-5.2 theory review rounds. User explicitly requested "many additional rounds of refinement" and "Econometrica level work."
5. "use GPT-5.2 for many additional rounds of refinement, above the usual amount. theory + estimation, we can NOT have slop. We need econometrica level work." — Extra theory review (GPT-5.2-pro), multiple revision cycles, structural model must be tight.

## Setup Results

- **Country:** usa
- **Domain:** Opioid prescribing regulation / physician-induced demand / addiction economics
- **Method:** DiD (staggered adoption of must-access PDMPs + prescribing limits)
- **Data era:** Modern (Medicare Part D 2013-2022, CDC WONDER, RAND OPTIC)
- **Risk appetite:** Novel angle — established data (Medicare Part D) + novel theoretical framing (sufficient statistics welfare analysis of prescribing regulation)
- **Other preferences:** Econometrica-caliber theory + estimation. Sufficient statistics approach. Extra GPT-5.2 refinement rounds. Theory review mandatory.
